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Abstract
Background: There is evidence that cytoreductive nephrectomy (CN) may be beneficial in 
metastatic renal cell carcinoma (mRCC). This has been studied predominantly in clear-cell RCC, 
with more limited data on the role of CN in patients with papillary histology.
Objective: To determine the benefit of CN in synchronous metastatic papillary RCC.
Design, setting, and participants: Using the International Metastatic Renal Cell Carcinoma 
Database Consortium (IMDC) database, a retrospective analysis was performed for patients with 
papillary mRCC treated with or without CN.
Outcome measurements and statistical analysis: Median overall survival (OS) and 
progression-free survival (PFS) were determined for both patient groups. Cox regression analysis 
was performed to control for imbalances in individual IMDC risk factors.
Results and limitations: In total, 647 patients with papillary mRCC were identified, of whom 
353 had synchronous metastatic disease. Of these, 109 patients were treated with CN and 244 
were not. The median follow-up was 57.1 mo (95% confidence interval [CI] 32.9–77.8) and the 
OS from the start of first-line targeted therapy for the entire cohort was 13.2 mo (95% CI 12.0–
16.1). Median OS for patients with CN was 16.3 mo, compared to 8.6 mo (p < 0.0001) in the no-
CN group. When adjusted for individual IMDC risk factors, the hazard ratio (HR) of death for CN 
was 0.62 (95% CI 0.45–0.85; p = 0.0031). Limitations include the retrospective nature of the 
analysis.
Conclusions: The use of CN in patients with mRCC and papillary histology appears to be 
associated with better survival compared to no CN after adjustment for risk criteria. Selection of 
appropriate candidates for CN is crucial. A clinical trial in this rare population may not be 
possible.
Patient summary: In a population of patients with advanced papillary kidney cancer, we found 
that surgical removal of the primary kidney tumor was associated with better overall survival.
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1. Introduction
Despite impressive advances in treatment, renal cell carcinoma (RCC) remains a significant 
global health issue, with approximately 30% of patients presenting with advanced disease 
[1]. The treatment landscape for metastatic RCC (mRCC) has undergone a dramatic 
transformation in recent years because of the introduction of molecularly targeted therapies 
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and novel immuno-oncology (IO) agents [2]. Despite these therapeutic advances, the 
management of mRCC still requires a multimodal approach, with the incorporation of 
systemic targeted and IO therapies, as well as selected use of radiation therapy and surgical 
interventions.
The evidence for surgical resection of the primary renal tumor in synchronous metastatic 
disease is derived from both observational studies and randomized trials. Evidence 
supporting the use of cytoreductive nephrectomy (CN) comes from data from prospective 
trials in the era of IFN therapy, as well as retrospective studies performed in the more 
modern, targeted therapy era. A pooled analysis of two prospective randomized clinical trials 
demonstrated that CN followed by IFN treatment was associated with a 5.8-mo increase in 
overall survival (OS) when compared to IFN alone (13.6 vs 7.8 mo) [3]. Similarly, 
retrospective analyses of real-world mRCC data sets have also suggested a survival benefit 
from CN among patients treated with targeted therapy [4,5]. By contrast, the recently 
reported phase 3 CARMENA clinical trial demonstrated that targeted therapy with sunitinib 
alone was noninferior to nephrectomy followed by sunitinib in International mRCC 
Database Consortium (IMDC) intermediate- and poor-risk patients with clear cell histology 
[6]. In general, the potential benefits of CN must be balanced carefully with the possible 
complications and morbidity of this procedure.
The majority of these studies have focused primarily on clear cell RCC (ccRCC), the most 
common RCC histological subtype. There are more limited data regarding the role of CN in 
non–clear-cell RCC (nccRCC). Within nccRCC pathology, the most common subtype is 
papillary RCC, accounting for approximately 10–15% of RCC cases. Papillary RCC has 
unique biological and clinical features compared to traditional ccRCC histology [7]. This 
includes more frequent genetic mutations in MET and FH, rather than the VHL alterations 
seen in ccRCC. Clinically, papillary RCC is characterized by diverse outcomes, with both 
indolent and aggressive tumors. Thus, the role of CN in papillary RCC may differ when 
compared to its ccRCC counterpart. Given this context, this study was designed to determine 
the benefit of CN in synchronous metastatic papillary RCC using the IMDC database.
2. Patients and methods
2.1. Patient population
Patient data were collected retrospectively from 38 international cancer centers included in 
the IMDC. The IMDC is a large, multi-institutional set comprising data for patients with 
metastatic RCC [8]. Inclusion criteria for this study were patients with metastatic RCC and 
papillary histology. We further divided this cohort into patients treated with targeted therapy 
without a history of nephrectomy, and those treated with CN, defined as nephrectomy 
performed after diagnosis of synchronous metastatic disease or within 90 d before diagnosis 
of metastatic disease [5].
Data were collected using uniform database software and templates. Baseline demographic, 
clinical, and laboratory data were collected, including variables found to have prognostic 
significance. Laboratory values were standardized against their respective institution upper 
limit of normal (ULN) and lower limit of normal (LLN) values as necessary. Outcomes 
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measured included (OS), progression free survival (PFS), and objective response rate (ORR) 
to first-line therapy. The data included patients accrued between 2005 and October 2017. 
This study received institutional review board approval from each participating center.
2.2. Statistical analysis
The primary outcome of this study was OS, defined as time from initiation of first-line 
targeted therapy to the date of death or censored at last follow-up. A secondary outcome was 
PFS, defined as time from initiation of targeted therapy to the date of progression, drug 
cessation, or censored at last follow-up. Median OS and PFS distributions were estimated 
using the Kaplan-Meier method. Cox proportional hazards regression was used to determine 
hazard ratios (HRs) after adjustment for baseline prognostic variables. This included 
adjusting for the IMDC prognostic factors: hemoglobin below the LLN, corrected calcium 
greater than the ULN, neutrophils above the ULN, platelets greater than the ULN, 
Karnofsky performance status (KPS) <80%, and time from diagnosis to treatment of <1 yr. 
The IMDC prognostic factors have been validated in metastatic papillary RCC [9]. Adjusted 
HRs and corresponding p values are reported. Statistical analyses were performed with SAS 
v.9.4 (SAS Institute, Cary, NC, USA), with statistical significance set at p < 0.05 (two-sided 
test).
3. Results
At the time of analysis, a total of 8798 patients with mRCC were included in the overall 
IMDC data set. Within this population, 647 patients were identified as having papillary 
histology. Of this subset, 538 underwent nephrectomy. Those who had a prior nephrectomy 
and then subsequently developed metastatic disease were excluded (n = 294) to isolate 
patients with synchronous metastatic disease. The final numbers for the analysis included 
109 patients without CN and 244 with CN. The median number of patients included by the 
contributing institutions was nine. The median follow-up for all patients was 57.1 mo (95% 
confidence interval [CI] 32.9–77.8). The median OS from the start of first-line targeted 
therapy for the entire cohort was 13.2 mo (95% CI 12.0–16.1).
Table 1 compares baseline characteristics for the CN and no- CN groups. Table 2 
summarizes the type of targeted therapy received and the number of subsequent lines of 
therapy. Patients who underwent CN were more likely to be younger (p = 0.0001) with 
better performance status (p = 0.0231). There was also a higher number of bone metastases 
in the CN group (p = 0.0281). The proportions of type 1 and type 2 histology were similar 
between the two groups (p = 0.902). Sunitinib was the most common first-line targeted 
therapy used in both groups. The ORR to first-line therapy did not differ between CN and 
no-CN (12% vs 5.9%; p = 0.2847).
The median OS for the CN group was 16.3 mo, compared to 8.6 mo in the no-CN group 
(Fig. 1; p < 0.0001). On multivariable analysis adjusted for IMDC prognostic factors, the 
HR for death was 0.62 (95% CI 0.45–0.85; p = 0.0031), translating into a 38% decrease in 
the risk of death with CN. After adjusting for additional prognostic imbalances including the 
IMDC criteria, age, and the presence of bone metastases, the HR improved to 0.55 (95% CI 
0.39–0.78; p = 0.0006). With regard to secondary outcomes, PFS also appeared to be 
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prolonged in the CN group at 5.1 mo, compared to 3.4 mo in the no-CN group (Fig. 2; p = 
0.0344). After adjusting for the IMDC factors, the HR for PFS was 0.82 (95% CI 0.61–1.10; 
p = 0.1822). When age and the presence of bone metastases were added to the regression 
model, the HR for PFS was 0.73 (95% CI 0.53–1.01; p = 0.0555). For comparative purposes, 
we performed an analysis of CN versus no-CN in the ccRCC population. In this ccRCC 
subset, median OS was 21.8 mo in the CN group, compared to 10.0 mo in the no-CN group 
(p < 0.0001).
We also performed a subgroup analysis by dividing the CN cohort into immediate systemic 
therapy (defined as within 90 d of surgery) and delayed systemic therapy (defined as >90 d 
from CN) groups. There was no significant survival difference between these two subgroups.
4. Discussion
The role of CN in the contemporary management of advanced kidney cancer has been well 
studied in retrospective studies, analyses of real-world data, and randomized controlled 
trials. Prior retrospective analyses of different data sets, including the IMDC and the 
National Cancer Data Base, have consistently revealed that CN appears to offer a survival 
benefit in ccRCC [5,10].
Although more limited than the literature on ccRCC, previous retrospective analyses have 
also suggested a benefit of CN in nccRCC [11,12]. It is important to note that nccRCC 
represents a diverse spectrum of pathological and clinical entities, with papillary RCC being 
the most common subtype. Aizer et al. [12] analyzed the role of CN in metastatic nccRCC 
using the Surveillance, Epidemiology, and End Results (SEER) database. In this more 
heterogeneous population, CN was associated with lower cancer-specific and all-cause 
mortality (HR 0.45, 95% CI 0.37–0.55; p < 0.001). Marchioni et al. [11] also examined the 
role of CN in nccRCC patients using an updated analysis of the SEER database. They again 
demonstrated a cancer-specific mortality benefit with CN (HR 0.38, 95% CI 0.30–0.47; p < 
0.001). In a subgroup analysis looking at patients with papillary RCC, CN was also 
associated with better cancer-specific mortality (HR 0.40, 95% CI 0.30–0.53; p < 0.001). 
None of these studies adjusted for potential confounders such as IMDC criteria, specifically 
for the time between diagnosis and systemic therapy.
The results of our analysis for patients with exclusively papillary RCC are consistent with 
these findings. In contrast to the SEER database, the IMDC is able to control for more 
specific prognostic variables, including performance status at initiation of systemic therapy 
and biochemical parameters. In our study, the group receiving CN were younger and had 
better performance status, probably reflecting an element of bias in surgical selection. We 
demonstrated that patients undergoing CN had significantly better OS, even when 
controlling for prognostic imbalances between these groups, including performance status, 
age, and the IMDC risk factors. A PFS benefit in favor of CN did not meet statistical 
significance in the multivariable analysis. The proportion of type 1 and type 2 histology was 
similar between these two groups, which is important given the clinical significance of these 
subtypes. To the best of our knowledge, our study represents the largest multivariable 
analysis exploring CN in papillary RCC. Given that advanced papillary RCC typically has 
Graham et al. Page 5













lower response rates to traditional VEGF targeted therapies, it may be even more important 
to achieve local tumor control and cytoreduction in this tumor subtype [13].
In contrast to these findings, the recently reported CARMENA randomized controlled trial 
demonstrated that sunitinib therapy alone appeared to be noninferior to CN followed by 
sunitinib in patients with intermediate and poor risk [6]. The results in the sunitinib-alone 
group were noninferior to those in the CN followed by sunitinib group with regard to OS 
(stratified HR for death, 0.89, 95% CI 0.71–1.10; upper bound of the 95% CI for 
noninferiority, ≤1.20).
Importantly, the CARMENA trial excluded patients with nccRCC and by definition 
excluded patients with favorable risk. In addition, patients randomized in this trial may not 
accurately reflect ideal CN candidates in a real-world setting, possibly because of a 
perceived lack of clinical equipoise [14]. This was evident in the slow accrual to the trial, 
which required a reduction in its sample size, and the unusually high number of IMDC poor-
risk patients in the cohort (43%). Prior studies using the IMDC database have suggested that 
patients with poorer risk, including those with four or more IMDC risk factors, do not 
appear to derive benefit from CN [5]. Thus, utilization of CN in this poor-risk population 
may have helped the trial meet its noninferiority endpoint. The efficacy of systemic therapy 
in papillary RCC is suboptimal, highlighting the importance of CN as a potential therapeutic 
strategy in metastatic disease.
In general, CN may be considered for patients with good performance status and limited or 
slow-growing metastatic disease. Symptomatic patients with ongoing hematuria or flank 
pain may also benefit from CN. It is important to discuss these cases in a multidisciplinary 
tumor board to consider CN feasibility, comorbidities, and an estimate of the overall 
prognosis to gain an insight into whether the patients will benefit from surgery. Thus, for 
patients with papillary RCC, careful patient selection for CN is crucial.
Another randomized trial (SURTIME trial) randomized mRCC patients to immediate CN 
followed by sunitinib versus delayed CN after three cycles of initial sunitinib [15,16]. A 
trend towards better OS for those with deferred nephrectomy was observed. This may in part 
be due to patient selection after initial sunitinib, in that patients who had a favorable tumor 
response went on to CN, while CN was aborted for those who had progressive disease. This 
trial may give treating physicians the comfort that delaying a decision on CN may be 
reasonable, especially for patients with intermediate or poor risk. Similar to the CARMENA 
trial, SURTIME included patients with ccRCC only, and thus may not be fully generalizable 
to those with nccRCC or papillary histology.
Limitations of our study include the retrospective nature of the analysis and the presence of 
inherent, unmeasured confounders that could not be adjusted for, despite multivariable 
analysis. Selection bias is another important limitation that is intrinsic to the retrospective 
design of the study. The IMDC uses a consecutive patient series to minimize selection bias. 
Given these limitations, a causal relationship between CN and survival cannot be definitively 
established. There was no central pathology review, as this was a multi-institutional study. 
Our data set only includes patients who are receiving active systemic therapy, and thus does 
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not include patients with mRCC undergoing active surveillance. Owing to low patient 
numbers, we were unable to perform a subgroup analysis looking at the relationship between 
a number of individual IMDC factors and benefit from CN. We were also unable to account 
for outcomes such as perioperative mortality and surgery-related morbidity.
5. Conclusions
In summary, in our data set it appears that CN is associated with better survival in metastatic 
papillary RCC, even when controlling for known prognostic imbalances between the groups. 
Given the lower response rates to targeted therapy in papillary RCC, achieving local tumor 
control may be particularly important in this pathological subtype. As in the more 
commonly studied ccRCC population, selection of patients for CN will be critical. 
Unfortunately, a prospective clinical trial in this rare subgroup may not be possible. As the 
treatment landscape for mRCC evolves, it will be important to reevaluate the role of CN in 
papillary RCC, particularly in combination with novel IO and MET targeted therapy.
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Fig. 1 –. 
Kaplan-Meier curve for overall survival (OS) for the CN and no-CN groups. CN = 
cytoreductive nephrectomy; HR = hazard ratio; CI = confidence interval; IMDC = 
International Metastatic Renal Cell Carcinoma Database Consortium.
1 Adjusted for IMDC prognostic factors.
2 Adjusted for IMDC prognostic factors, age, and bone metastases.
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Fig. 2 –. 
Kaplan-Meier curve for progression-free survival (PFS) for the CN and no-CN groups. CN = 
cytoreductive nephrectomy; HR = hazard ratio; CI = confidence interval; IMDC = 
International Metastatic Renal Cell Carcinoma Database Consortium.
1 Adjusted for IMDC prognostic factors.
2 Adjusted for IMDC prognostic factors, age, and bone metastases.
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Table 2 –
Baseline treatment characteristics for the CN and no-CN groups.
No CN (N = 109) CN (N = 244) p value
First-line therapy, n/N (%)
 Sunitinib 59/109 (54) 134/244 (55)
 Sorafenib 3/109 (2.8) 31/244 (13)
 Temsirolimus 25/109 (23) 31/244 (13)
 Pazopanib 12/109 (11) 19/244 (7.8)
 Other 10/109 (9.1) 29/244 (12)
Second-line therapy, n/N (%) 43/109 (39) 137/244 (56) 0.0037
Third-line therapy, n/N (%) 17/109 (16) 58/244 (24) 0.0828
Fourth-line therapy, n/N (%) 4/109 (3.7) 16/244 (6.6) 0.2783
CN = cytoreductive nephrectomy.
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